Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS). - 2025
Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).
Fielding, Roger A; Rolland, Yves; Bruyère, Olivieret al.
Mobility disability; Older adults; Physical performance; Sarcopenia; Sarcopenic obesity; Humans; Male; Female; Aged; Aged, 80 and over; Hand Strength/physiology; Walking Speed/physiology; Risk Factors; Sarcopenia/diagnosis; Sarcopenia/physiopathology; Sarcopenia/epidemiology; Mobility Limitation; Obesity/diagnosis; Obesity/epidemiology; Obesity/physiopathology; Hand Strength; Obesity; Walking Speed; Geriatrics and Gerontology
Abstract :
[en] [en] BACKGROUND: Aging is associated with a progressive change of body composition characterized by muscle mass decline and accumulation of adipose tissue that can lead to sarcopenia and obesity, respectively. The prevalence of sarcopenia is poorly known given the different parameters and thresholds in proposed definitions. The combination of obesity (defined as a percentage of body fat mass of > 25% in men and > 35% in women) and sarcopenia (SO) adds complexity to the characterization of this pathology. SARA-OBS aimed to better characterize sarcopenia (including SO) and its consequences on physical function over time, in community-dwelling older adults at risk of mobility disability, and to support the design of further interventional clinical trials.
METHODS: This was an international, multicenter, 6-month observational study of men and women aged ≥ 65 years suffering from sarcopenia according to the Foundation for the National Institute of Health (FNIH) cut-offs for Sarcopenia and with a Short Physical Performance Battery (SPPB) ≤ 8. The primary endpoint was the change in Gait Speed (GS) in the 400-meter walking test (400MWT), reported at baseline and at Month 6/ end of the study (EOS). Secondary endpoints included changes in handgrip strength (HGS), physical performance (6-Minute Walking Distance [6MWD], SPPB), the Physical Function Domain (PF-10) sub-score and total score of the SF-36 survey and the Sarcopenia and Quality of Life (SarQoL) questionnaire.
RESULTS: Overall, the mean (± SD) change from baseline to Month 6/EOS in 400MWT GS was - 0.027 ± 0.171 m/sec (p = 0.064). Both GS and 6MWD decreased significantly in subgroup with GS ≥ 0.8 m/sec at baseline (-0.047 ± 0.185 m/sec; p = 0.017 and - 24.01 ± 68.24 m; p = 0.001, respectively). In subgroup with SPPB = 8 at baseline, 6MWD also decreased (-36.80 ± 67.60 m; p < 0.001). We observed a significant change from baseline for 6MWD in the SO subgroup (-18.30 ± 81.95 m; p = 0.013). Neither HGS nor SarQoL changed significantly from baseline to Month 6/EOS.
CONCLUSIONS: SARA-OBS results contribute to defining subgroups of older adults at risk of functional decline over 6 months, specifically subjects with SPPB = 8, affecting GS and the 6MWD. Additionally, the SO subpopulation exhibited a relevant deterioration in physical function as evaluated by the 6MWD.
TRIAL REGISTRATION: NCT03021798 (ClinicalTrials.gov). Date of registration 16/01/2017.
Disciplines :
Geriatrics
Author, co-author :
Fielding, Roger A; Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington St, Boston, MA, 02111, USA
Rolland, Yves; IHU HealthAge, Centre Hospitalo-Universitaire de Toulouse, CERPOP UMR 1295, University of Toulouse III, Toulouse, France
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Desvarieux, Moise; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA ; METHODS Core, Centre de Recherche Epidémiologie et Statistique Paris Sorbonne Cité (CRESS), Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1153, Paris, France
Donini, Lorenzo M; Department of Experimental Medicine, Food Science and Human Nutrition Research Unit, Sapienza University of Rome, Rome, Italy
Incalzi, Raffaele Antonelli; Internal Medicine Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy
Muscaritoli, Maurizio; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
Tchalla, Achille; CHU de Limoges, Pôle HU Gérontologie Clinique, 2 Avenue Martin-Luther King, Limoges, 87042, France
Bonnefoy, Marc; CHLS, Pavillon 4E, Service Universitaire de Médecine gériatrique, INSERM 1060, UCBL LYON 1, Pierre Benite CEDEX, 69495, France
Rondanelli, Mariangela; Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, 27100, Italy
Van Maanen, Rob; BIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy
Mariani, Jean; BIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy ; Sorbonne Université, CNRS - Institut de Biologie Paris Seine (UMR B2A), Paris, 75005, France
Margalef, Carole; BIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy
Del Signore, Susanna; Bluecompanion Ltd, 12a Neville Court, Abbey Road, London, NW8 9DD, UK ; Bluecompanion France, 41 route de la Bernon, Jambville, 78440, France
Tourette, Cendrine; BIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy
Dioh, Waly; BIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy. waly.dioh@biophytis.com
Veillet, Stanislas; BIOPHYTIS SA - Sorbonne Université, 4 Place de Jussieu, Paris Cedex 05, 75252, Italy
Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).
R.A.F. is partially supported by the US Department of Agriculture (USDA), under agreement No. 58-8050-9-004, by NIH Boston Claude D. Pepper Center (OAIC; 1P30AG031679). Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA.
A.J. Cruz-Jentoft J.P. Baeyens J.M. Bauer Y. Boirie T. Cederholm F. Landi et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people Age Ageing 39 412 23
V. Santilli A. Bernetti M. Mangone M. Paoloni Clinical definition of sarcopenia Clin Cases Min Bone Metab 11 177 80
I. Janssen D.S. Shepard P.T. Katzmarzyk R. Roubenoff The healthcare costs of sarcopenia in the United States J Am Geriatr Soc 52 80 5
S. Goates K. Du M.B. Arensberg T. Gaillard J. Guralnik S.L. Pereira Economic impact of hospitalizations in US adults with sarcopenia J Frailty Aging 8 93 9 1:STN:280:DC%2BB3M%2FmslWquw%3D%3D
S.D. Anker J.E. Morley S. von Haehling Welcome to the ICD-10 code for sarcopenia J Cachexia Sarcopenia Muscle 7 512 4
A.J. Cruz-Jentoft G. Bahat J. Bauer Y. Boirie O. Bruyère T. Cederholm et al. Sarcopenia: revised European consensus on definition and diagnosis Age Ageing 48 16 31
L.A. Schaap A. Koster M. Visser Adiposity Muscle mass, and muscle strength in relation to functional decline in older persons Epidemiol Rev 35 51 65
D.P. Leong K.K. Teo S. Rangarajan P. Lopez-Jaramillo A. Avezum A. Orlandini et al. Prognostic value of grip strength: findings from the prospective urban rural epidemiology (PURE) study Lancet 386 266 73
Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69:547–58.
W. Kemmler S. von Stengel K. Engelke C. Sieber E. Freiberger Prevalence of sarcopenic obesity in Germany using established definitions: baseline data of the FORMOsA study Osteoporos Int 27 275 81 1:STN:280:DC%2BC287ntFCrug%3D%3D
P.M. Cawthon T. Manini S.M. Patel A. Newman T. Travison D.P. Kiel et al. Putative Cut-Points in sarcopenia components and incident adverse health outcomes: an SDOC analysis J Am Geriatr Soc 68 1429 37
J.-Y. Reginster C. Beaudart N. Al-Daghri B. Avouac J. Bauer N. Bere et al. Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults Aging Clin Exp Res 33 3 17
G. van Abellan W. Cameron Chumlea S. Gillette-Guyonet M. Houles C. Dupuy Y. Rolland et al. Clinical trials on sarcopenia: methodological issues regarding phase 3 trials Clin Geriatr Med 27 471 82
Y.M. Rolland M. Cesari M.E. Miller B.W. Penninx H.H. Atkinson M. Pahor Reliability of the 400-M Usual-Pace walk test as an assessment of mobility limitation in older adults J Am Geriatr Soc 52 972 6
T. Rantanen J.M. Guralnik D. Foley K. Masaki S. Leveille J.D. Curb et al. Midlife hand grip strength as a predictor of old age disability JAMA 281 558 60 1:STN:280:DyaK1M7ksVOisw%3D%3D
T. Rantanen T. Harris S.G. Leveille M. Visser D. Foley K. Masaki et al. Muscle strength and body mass index as long-term predictors of mortality in initially healthy men J Gerontol Biol Sci Med Sci 55 M168 173 1:STN:280:DC%2BD3c3lsVOnug%3D%3D
J.M. Guralnik E.M. Simonsick L. Ferrucci R.J. Glynn L.F. Berkman D.G. Blazer et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission J Gerontol 49 M85 94 1:STN:280:DyaK2c7nt1aitw%3D%3D
C. Beaudart J.Y. Reginster J. Petermans S. Gillain A. Quabron M. Locquet et al. Quality of life and physical components linked to sarcopenia: the sarcophage study Exp Gerontol 69 103 10 1:STN:280:DC%2BC2Mfktl2ltg%3D%3D
C. Beaudart E. Biver J.-Y. Reginster R. Rizzoli Y. Rolland I. Bautmans et al. Validation of the SarQoL®, a specific health-related quality of life questionnaire for sarcopenia: validation of the SarQoL® questionnaire J Cachexia Sarcopenia Muscle 8 238 44
C. Beaudart M. Locquet J.-Y. Reginster L. Delandsheere J. Petermans O. Bruyère Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions Aging Clin Exp Res 30 307 13
The SF-36v2® Health Survey | Quality Metric. Quality Metric | We Measure Health. https://www.qualitymetric.com/health-surveys/the-sf-36v2-health-survey/. Accessed 11 Jan 2024.
J.E. Morley Pharmacologic options for the treatment of sarcopenia Calcif Tissue Int 98 319 33 1:CAS:528:DC%2BC2MXhtVGmurjF
M. Cesari B.W.J.H. Penninx M. Pahor F. Lauretani A.M. Corsi G. Rhys Williams et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study J Gerontol Biol Sci Med Sci 59 242 8
F.-C. Hsu S.B. Kritchevsky Y. Liu A. Kanaya A.B. Newman S.E. Perry et al. Association between inflammatory components and physical function in the health, aging, and body composition study: a principal component analysis approach J Gerontol Biol Sci Med Sci 64 581 9
L.A. Schaap S.M.F. Pluijm D.J.H. Deeg T.B. Harris S.B. Kritchevsky A.B. Newman et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength J Gerontol Biol Sci Med Sci 64 1183 9
L.A. Schaap S.M.F. Pluijm D.J.H. Deeg M. Visser Inflammatory markers and loss of muscle mass (sarcopenia) and strength Am J Med 119 e5269 17
J.A. Batsis T.A. Mackenzie F. Lopez-Jimenez S.J. Bartels Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National health and nutrition examination surveys 1999–2004 Nutr Res 35 1031 9 1:CAS:528:DC%2BC2MXhs1Cqu7vK
E.A. Said I. Al-Reesi N. Al-Shizawi S. Jaju M.S. Al-Balushi C.Y. Koh et al. Defining IL-6 levels in healthy individuals: A meta-analysis J Med Virol 93 3915 24 1:CAS:528:DC%2BB3cXitl2nu7%2FE
N. Shokri-Mashhadi S. Moradi Z. Heidari S. Saadat Association of Circulating C-reactive protein and high-sensitivity C-reactive protein with components of sarcopenia: A systematic review and meta-analysis of observational studies Exp Gerontol 150 111330 1:CAS:528:DC%2BB3MXhs1yntrvM
U. Lindemann S. Krumpoch C. Becker C.C. Sieber E. Freiberger The course of gait speed during a 400m walk test of mobility limitations in community-dwelling older adults Z Gerontol Geriatr 54 768 74
S. Perera K.V. Patel C. Rosano S.M. Rubin S. Satterfield T. Harris et al. Gait speed predicts incident disability: A pooled analysis J Gerontol Biol Sci Med Sci 71 63 71
J.P.H. Wilding R.L. Batterham S. Calanna M. Davies L.F. Van Gaal I. Lingvay et al. Once-Weekly semaglutide in adults with overweight or obesity N Engl J Med 384 989 1002 1:CAS:528:DC%2BB3MXntVWlur8%3D
S. Studenski Gait speed and survival in older adults JAMA 305 50 1:CAS:528:DC%2BC3MXkslWhsA%3D%3D
A.B. Newman E.M. Simonsick B.L. Naydeck R.M. Boudreau S.B. Kritchevsky M.C. Nevitt et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability JAMA 295 2018 26 1:CAS:528:DC%2BD28Xkt12mt74%3D
G.H. Guyatt M.J. Sullivan P.J. Thompson E.L. Fallen S.O. Pugsley D.W. Taylor et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure Can Med Assoc J 132 919 23 1:STN:280:DyaL2M7ltFCksw%3D%3D
E.M. Simonsick E. Fan J.L. Fleg Estimating cardiorespiratory fitness in Well-Functioning older adults: treadmill validation of the long distance corridor walk J Am Geriatr Soc 54 127 32
P.L. Enright M.A. McBurnie V. Bittner R.P. Tracy R. McNamara A. Arnold et al. The 6-min walk test: a quick measure of functional status in elderly adults Chest 123 387 98
T. Troosters R. Gosselink M. Decramer Six minute walking distance in healthy elderly subjects Eur Respir J 14 270 4 1:STN:280:DyaK1MvktlChsQ%3D%3D
S.P. Sayers J.M. Guralnik A.B. Newman J.S. Brach R.A. Fielding Concordance and discordance between two measures of lower extremity function: 400 meter self-paced walk and SPPB Aging Clin Exp Res 18 100 6
M. Pahor J.M. Guralnik W.T. Ambrosius S. Blair D.E. Bonds T.S. Church et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial JAMA 311 2387 1:CAS:528:DC%2BC2cXhsFemt7%2FO
The LIFE Study Investigators* [*See Appendix for List of LIFE Study Investigators]. Effects of a physical activity intervention on measures of physical performance: results of the lifestyle interventions and independence for elders pilot (LIFE-P) study. The journals of gerontology series A: biological sciences and medical sciences. 2006;61:1157–65.
R. Bernabei F. Landi R. Calvani M. Cesari S. Del Signore S.D. Anker et al. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) BMJ 377 e068788
R.M. Dodds H.E. Syddall R. Cooper M. Benzeval I.J. Deary E.M. Dennison et al. Grip strength across the life course: normative data from twelve British studies PLoS ONE 9 e113637
Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985)2003;95:1851–60.
J. Sallinen S. Stenholm T. Rantanen M. Heliövaara P. Sainio S. Koskinen Hand-grip strength cut points to screen older persons at risk for mobility limitation J Am Geriatr Soc 58 1721 6
G.J. Grosicki T.G. Travison H. Zhu J. Magaziner E.F. Binder M. Pahor et al. Application of Cut-Points for low muscle strength and lean mass in Mobility-Limited older adults J Am Geriatr Soc 68 1445 53
B. Manrique-Espinoza A. Salinas-Rodríguez O. Rosas-Carrasco L.M. Gutiérrez-Robledo J.A. Avila-Funes Sarcopenia is associated with physical and mental components of Health-Related quality of life in older adults J Am Med Dir Assoc 18 e6361 5
A. Geerinck O. Bruyère M. Locquet J.-Y. Reginster C. Beaudart Evaluation of the responsiveness of the SarQoL® questionnaire, a Patient-Reported outcome measure specific to sarcopenia Adv Ther 35 1842 58
C. Guillamón-Escudero A. Diago-Galmés D. Zuazua Rico A. Maestro-González J.M. Tenías-Burillo J.M. Soriano et al. SarQoL questionnaire in Community-Dwelling older adults under EWGSOP2 sarcopenia diagnosis algorithm: A new screening method?? Int J Environ Res Public Health 19 8473
A.S. Ryan G. Li Skeletal muscle myostatin gene expression and sarcopenia in overweight and obese middle-aged and older adults JCSM Clin Rep 6 137 42
L.M. Donini L. Busetto J.M. Bauer S. Bischoff Y. Boirie T. Cederholm et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review Clin Nutr 39 2368 88
L.M. Donini L. Busetto S.C. Bischoff T. Cederholm M.D. Ballesteros-Pomar J.A. Batsis et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement Clin Nutr 41 990 1000 1:CAS:528:DC%2BB38Xht1CntbzJ
M. Locquet C. Beaudart J.-Y. Reginster O. Bruyère Association between the decline in muscle health and the decline in bone health in older individuals from the sarcophage cohort Calcif Tissue Int 104 273 84 1:CAS:528:DC%2BC1cXitl2iurvI
L. Lengelé P. Moehlinger O. Bruyère M. Locquet J.-Y. Reginster C. Beaudart Association between changes in nutrient intake and changes in muscle strength and physical performance in the sarcophage cohort Nutrients 12 3485
F. Petermann-Rocha V. Balntzi S.R. Gray J. Lara F.K. Ho J.P. Pell et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis J Cachexia Sarcopenia Muscle 13 86 99
